Citigroup
CARM

Citigroup’s Carisma Therapeutics CARM Stock Holding History

Citigroup’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,274
Closed -$3.09K – 6103
2025
Q3 		$3.09K Buy
+11,274
New +$3.73K ﹤0.01% 5372
2025
Q1 		– Sell
-10
Closed -$4 – 5618
2024
Q4 		$4 Hold
10
– – ﹤0.01% 5789
2024
Q3 		$10 Sell
10
-3,502
-100% -$3.79K ﹤0.01% 5620
2024
Q2 		$5.34K Sell
3,512
-1,487
-30% -$2.22K ﹤0.01% 5250
2024
Q1 		$11.3K Buy
4,999
+1,184
+31% +$2.85K ﹤0.01% 5172
2023
Q4 		$11.2K Buy
3,815
+3,802
+29,246% +$11.3K ﹤0.01% 5169
2023
Q3 		$55 Sell
13
-7,929
-100% -$50.2K ﹤0.01% 5517
2023
Q2 		$69.7K Buy
+7,942
New +$43.2K ﹤0.01% 4438
2023
Q1 		– Sell
-7
Closed -$86 – 5525
2022
Q4 		$86 Sell
7
-123
-95% -$1.29K ﹤0.01% 5643
2022
Q3 		$1K Sell
130
-132
-50% -$1.8K ﹤0.01% 5609
2022
Q2 		$4K Sell
262
-362
-58% -$4.14K ﹤0.01% 5664
2022
Q1 		$8K Sell
624
-2,350
-79% -$32.8K ﹤0.01% 5629
2021
Q4 		$48K Buy
2,974
+1,571
+112% +$31.6K ﹤0.01% 5080
2021
Q3 		$22K Sell
1,403
-45,152
-97% -$2.17M ﹤0.01% 5191
2021
Q2 		$4.3M Buy
46,555
+45,908
+7,096% +$2.93M ﹤0.01% 2027
2021
Q1 		$34K Buy
647
+622
+2,488% +$29.3K ﹤0.01% 4924
2020
Q4 		$1K Hold
25
– – ﹤0.01% 7271
2020
Q3 		$1K Hold
25
– – ﹤0.01% 7355
2020
Q2 		$0 Hold
25
– – ﹤0.01% 7543
2020
Q1 		$0 Hold
25
– – ﹤0.01% 7605
2019
Q4 		$1K Sell
25
-5
-17% -$115 ﹤0.01% 7587
2019
Q3 		$1K Hold
30
– – ﹤0.01% 7598
2019
Q2 		$1K Hold
30
– – ﹤0.01% 7662
2019
Q1 		$1K Hold
30
– – ﹤0.01% 7569
2018
Q4 		$1K Hold
30
– – ﹤0.01% 7556
2018
Q3 		$1K Hold
30
– – ﹤0.01% 7649
2018
Q2 		$1K Hold
30
– – ﹤0.01% 7515
2018
Q1 		$1K Hold
30
– – ﹤0.01% 7427
2017
Q4 		$0 Hold
30
– – ﹤0.01% 7552
2017
Q3 		$1K Buy
30
+5
+20% +$140 ﹤0.01% 7101
2017
Q2 		$1K Hold
25
– – ﹤0.01% 7120
2017
Q1 		$1K Hold
25
– – ﹤0.01% 7067
2016
Q4 		$1K Sell
25
-5
-17% -$220 ﹤0.01% 7103
2016
Q3 		$2K Hold
30
– – ﹤0.01% 6916
2016
Q2 		$1K Sell
30
-3
-9% -$76 ﹤0.01% 6969
2016
Q1 		$0 Buy
33
+3
+10% +$41 ﹤0.01% 7472
2015
Q4 		$2K Hold
30
– – ﹤0.01% 7249
2015
Q3 		$1K Hold
30
– – ﹤0.01% 7136
2015
Q2 		$2K Buy
30
+11
+58% +$1.55K ﹤0.01% 7109
2015
Q1 		$4K Sell
19
-75
-80% -$16.4K ﹤0.01% 6757
2014
Q4 		$22K Buy
94
+31
+49% +$6.95K ﹤0.01% 6161
2014
Q3 		$14K Buy
63
+55
+688% +$13.1K ﹤0.01% 6087
2014
Q2 		$2K Sell
8
-8
-50% -$1.98K ﹤0.01% 6724
2014
Q1 		$6K Buy
+16
New +$4.79K ﹤0.01% 6532

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

Citigroup's CARM Position: Q4 2025 in Review

Citigroup sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 11,274 shares — an estimated $3.09K sold.

Citigroup first reported a position in CARM in Q1 2014 and held it in 44 quarters. The position peaked at $4.3M in Q2 2021. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • Citigroup reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 11,274 Carisma Therapeutics shares in Q4 2025, an estimated $3.09K.
  • Citigroup first reported a position in Carisma Therapeutics in Q1 2014 and held it in 44 quarters.
  • Citigroup's Carisma Therapeutics position peaked at $4.3M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.